GSK
GlaxoSmithKline opens new £56 million facility in Hertfordshire
April 19, 2016Manufacturing and Production Andrew Witty, GSK, GlaxoSmithKline, Sir Andrew Witty, ellipta, facility, george freeman, inhalers, manufacturing, new, respiratory, ware
GlaxoSmithKline has opened a new £56 million manufacturing facility in Hertfordshire, South-East England. The facility in Ware will create 150 …
Albumedix technology extends dosing interval in Behring haemophilia B drug
March 22, 2016Manufacturing and Production, Research and Development Albumedix, GSK, Idelvion, Novozymes, VELTIS, haemophilia B
Novozymes subsidiary Albumedix has scored another big pharma tie-up for its albumin-based half-life extension technology VELTIS, which this time is …
Sir Andrew Witty announces decision to step down as CEO of GSK
March 17, 2016Medical Communications, Research and Development Andrew Witty, GSK, GlaxoSmithKline, Neil Woodford, Sir Andrew Witty, Witty, gsk break up, gsk split, retirement, steps down
Sir Andrew Witty has announced his decision to retire from his role as chief executive officer of pharmaceutical giant, GlaxoSmithKline …
GSK’s asthma drug meets primary goal in safety study for children
March 17, 2016Research and Development Advair Diskus, GSK, asthma, drug trial
GlaxoSmithKline (LSE: GSK) said on Thursday its asthma drug met the primary end point in a second study for children. …
GSK establish cell and gene therapy collaboration with Miltenyi Biotec
March 16, 2016Medical Communications, Research and Development GSK, GlaxoSmithKline, cell and gene therapy, collaboration, miltenyi biotec
GlaxoSmithKline (NYSE:GSK) has announced a strategic collaboration with Miltenyi Biotec that will see GSK’s expertise in developing cell and gene …
GSK terminates Five Prime Therapeutics mesothelioma collaboration
March 14, 2016Research and Development, Sales and Marketing Five Prime Therapeutics, GSK, mesothelioma
GSK is to back out of a licensing deal with California-based Five Prime Therapeutics to develop a mesothelioma drug. Announcing …
MSF challenges Pfizer’s pneumonia vaccine patent in India
March 11, 2016Medical Communications, Research and Development, Sales and Marketing GSK, Pfizer, Prevnar 13, pneumonia vaccine
The charity Médecins Sans Frontières (MSF) has formally opposed Pfizer’s bid to obtain a patent for the pneumonia vaccine PCV13, …
Two-drug combo shown to significantly shrink breast cancer in days
March 10, 2016Medical Communications, Research and Development GSK, Herceptin, Novartis, Roche, Tyverb
Results of a clinical trial have revealed that Novartis’ Tyverb (lapatinib), in combination with Roche’s Herceptin (trastuzumab), can significantly shrink …
Genmab ends ofatumumab trials for autoimmune conditions; to focus on multiple sclerosis
March 9, 2016Research and Development Arzerra, GSK
Danish drug-company Genmab (Nasdaq Copenhagen: GEN) said it will discontinue the late-stage trials for Arzerra (ofatumumab) to develop a treatment for …
GSK says long-term study for Nucala backs safety profile
March 8, 2016Manufacturing and Production, Research and Development GSK, GlaxoSmithKline, Nucala, asthma
UK pharma major GlaxoSmithKline (LSE: GSK) said its asthma drug, Nucala (mepolizumab) showed a similar safety profile in a long-term …
ViiV completes BMS HIV pipeline purchase
February 23, 2016Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV
ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …
GSK and Adaptimmune expand R&D collaboration
February 3, 2016Research and Development Adaptimmune, GSK, T-cell therapy, immunotherapy, liposarcoma, rare cancer, sarcoma
Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, to run clinical trials of Adaptimmune’s potential …
GSK and Sanofi considering developing Zika vaccine
January 26, 2016Manufacturing and Production GSK, Sanofi, World Health Organisation, Zika virus, microcephaly
Pharma companies Sanofi and GSK are reviewing the possibility of using their respective inoculation technologies to develop a vaccine for …
Big pharma and UK universities launch £40m innovation fund
January 25, 2016Research and Development, Sales and Marketing Apollo, AstraZeneca, GSK, GlaxoSmithKline, Johnson & Johson, UCL, University College London, University of Cambridge, collaboration, imperial college london, joint venture
A consortium of big pharma companies and university with world-leading medical research facilities is to invest £40 million, to “significantly …
GSK ‘in discussions’ over $1 billion tech deal with Qualcomm
January 21, 2016Medical Communications GSK, beyond the pill, digital pharma, joint venture, qualcomm
GlaxoSmithKline and telecoms giant Qualcomm are reportedly discussing a joint venture agreement worth as much as $1 billion, as the …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
